Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2013

Study Completion Date

March 31, 2014

Conditions
Acute Lymphoblastic LeukemiaALLAcute Myelogenous LeukemiaAMLChronic Myelogenous LeukemiaMyelodysplastic SyndromeMyeloproliferative DisorderHodgkin LymphomaNon-Hodgkin LymphomaNon-malignant Diseases Requiring Allogeneic HSCT
Interventions
BIOLOGICAL

IL-2

"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed \>grade I side effects to IL-2 and has not developed \>grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00539695 - Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | Biotech Hunter | Biotech Hunter